Oncology / Myeloproliferative Neoplasms

patient care perspectives by Katherine Walsh, MD, FACP

Patients with polycythemia vera (PV) who are nonadherent to cytoreductive and/or antithrombotic therapy are at an increased risk of thrombotic even...READ MORE

Oncology / Myeloproliferative Neoplasms

patient care perspectives by Ruben A. Mesa, MD, FACP

First-line hydroxyurea is a therapeutic mainstay for cytoreduction in patients with polycythemia vera (PV); however, not all individuals with PV me...READ MORE

Oncology / Myeloproliferative Neoplasms

expert roundtables by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP

Achieving durable cytoreduction and adequate symptom relief in patients with polycythemia vera (PV) is a primary treatment challenge. Individual re...READ MORE

Oncology / Myeloproliferative Neoplasms

expert roundtables by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP

Symptoms of advanced myeloproliferative neoplasms (MPN) negatively impact quality of life and include fatigue, night sweats, itching, bone/muscle p...READ MORE